Allergy and coronavirus disease (COVID-19) international survey: Real-life data from the allergy community during the pandemic

  1. Tanno, Luciana Kase
  2. Demoly, Pascal
  3. Martin, Bryan
  4. Berstein, Jonathan
  5. Morais-Almeida, Mario
  6. Levin, Michael
  7. Fiocchi, Alessandro
  8. Sánchez-Borges, Mario
  9. Caraballo, Luis R.
  10. Wong, Gary
  11. Ortega-Martell, José Antonio
  12. Rouadi, Philip
  13. Yáñez, Anahí
  14. Wang, Liang Lu
  15. Peden, David B.
  16. Chikhladze, Manana
  17. González-Díaz, Sandra N.
  18. Fontaine, Jean-François
  19. Sublett, James
  20. Sublett, James
  21. Passalacqua, Giovanni
  22. Ansotegui, Ignacio J.
  23. Ebisawa, Motohiro
  24. Senna, Gianenrico
  25. Caminati, Marco

Download
1-s2.0-S1939455121000090-main.pdf 1,25MB
WeightNameValue
1000 Titel
  • Allergy and coronavirus disease (COVID-19) international survey: Real-life data from the allergy community during the pandemic
1000 Autor/in
  1. Tanno, Luciana Kase |
  2. Demoly, Pascal |
  3. Martin, Bryan |
  4. Berstein, Jonathan |
  5. Morais-Almeida, Mario |
  6. Levin, Michael |
  7. Fiocchi, Alessandro |
  8. Sánchez-Borges, Mario |
  9. Caraballo, Luis R. |
  10. Wong, Gary |
  11. Ortega-Martell, José Antonio |
  12. Rouadi, Philip |
  13. Yáñez, Anahí |
  14. Wang, Liang Lu |
  15. Peden, David B. |
  16. Chikhladze, Manana |
  17. González-Díaz, Sandra N. |
  18. Fontaine, Jean-François |
  19. Sublett, James |
  20. Sublett, James |
  21. Passalacqua, Giovanni |
  22. Ansotegui, Ignacio J. |
  23. Ebisawa, Motohiro |
  24. Senna, Gianenrico |
  25. Caminati, Marco |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-01-31
1000 Erschienen in
1000 Quellenangabe
  • 14(2):100515
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1016/j.waojou.2021.100515 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847410 |
1000 Ergänzendes Material
  • https://www.worldallergyorganizationjournal.org/article/S1939-4551(21)00009-0/fulltext#supplementaryMaterial |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: The COVID-19 outbreak brought an unprecedented challenge to the world. Knowledge in the field has been increasing exponentially and the main allergy societies have produced guidance documents for better management of allergic patients during this period. However, few publications so far have provided real-life data from the allergy community concerning allergy practice during the COVID-19 outbreak. Therefore, we proposed an international survey on the management of allergic patients during the current pandemic.METHODS: We performed an online survey undertaken to reach out the worldwide allergy community by e-mail and social media. The web-based questionnaire contained 24 questions covering demographic data from the participants, clinical practice during this period, and questions related to the new international classification and coding tools addressed for COVID-19. It was circulated for 8 weeks and had anonymous and volunteer context.RESULTS: Data are presented for 635 participants from 78 countries of all continents. Allergists with long-term professional experience were the main audience. As expected, we received many responses as “I have no data” or “I don't know” to the questions of the survey. However, most with more experience on managing allergic patients during the pandemic agreed that patients suffering from allergic or hypersensitivity conditions have no increased risk of contracting COVID-19 or developing SARS CoV-2. Also, participants mentioned that none of the allergy treatments (inhaled corticosteroids, allergen immunotherapy, biological agents) increased the risk of contracting COVID-19 infection including severe presentations.CONCLUSION: The data presented are a starting point in the process of getting feedback on all the recommendations provided by the allergy societies; it could also be the basis of new strategies to support health professionals while new COVID-19 specific treatments and vaccines are being explored. The information here presented intends to be helpful to the community but represents a course of action in a highly specific situation due to the state of emergency, and it should be helpful to health systems.
1000 Sacherschließung
lokal Allergen immunotherapy
lokal Inhaled steroids
gnd 1206347392 COVID-19
lokal Biological agents
lokal Prevention
lokal Allergy
lokal Asthma
lokal Treatment
lokal Coronavirus
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/VGFubm8sIEx1Y2lhbmEgS2FzZQ==|https://frl.publisso.de/adhoc/uri/RGVtb2x5LCBQYXNjYWw=|https://frl.publisso.de/adhoc/uri/TWFydGluLCBCcnlhbg==|https://frl.publisso.de/adhoc/uri/QmVyc3RlaW4sIEpvbmF0aGFu|https://frl.publisso.de/adhoc/uri/TW9yYWlzLUFsbWVpZGEsIE1hcmlv|https://frl.publisso.de/adhoc/uri/TGV2aW4sIE1pY2hhZWw=|https://frl.publisso.de/adhoc/uri/RmlvY2NoaSwgQWxlc3NhbmRybw==|https://frl.publisso.de/adhoc/uri/U8OhbmNoZXotQm9yZ2VzLCBNYXJpbw==|https://frl.publisso.de/adhoc/uri/Q2FyYWJhbGxvLCBMdWlzIFIu|https://frl.publisso.de/adhoc/uri/V29uZywgR2FyeQ==|https://frl.publisso.de/adhoc/uri/T3J0ZWdhLU1hcnRlbGwsIEpvc8OpIEFudG9uaW8=|https://frl.publisso.de/adhoc/uri/Um91YWRpLCBQaGlsaXA=|https://frl.publisso.de/adhoc/uri/WcOhw7FleiwgQW5haMOt|https://frl.publisso.de/adhoc/uri/V2FuZywgTGlhbmcgTHU=|https://frl.publisso.de/adhoc/uri/UGVkZW4sIERhdmlkIEIu|https://frl.publisso.de/adhoc/uri/Q2hpa2hsYWR6ZSwgTWFuYW5h|https://frl.publisso.de/adhoc/uri/R29uesOhbGV6LUTDrWF6LCBTYW5kcmEgTi4=|https://frl.publisso.de/adhoc/uri/Rm9udGFpbmUsIEplYW4tRnJhbsOnb2lz|https://frl.publisso.de/adhoc/uri/U3VibGV0dCwgSmFtZXM=|https://frl.publisso.de/adhoc/uri/U3VibGV0dCwgSmFtZXM=|https://frl.publisso.de/adhoc/uri/UGFzc2FsYWNxdWEsIEdpb3Zhbm5p|https://frl.publisso.de/adhoc/uri/QW5zb3RlZ3VpLCBJZ25hY2lvIEou|https://frl.publisso.de/adhoc/uri/RWJpc2F3YSwgTW90b2hpcm8=|https://frl.publisso.de/adhoc/uri/U2VubmEsIEdpYW5lbnJpY28=|https://frl.publisso.de/adhoc/uri/Q2FtaW5hdGksIE1hcmNv
1000 Label
1000 Förderer
  1. Novartis |
  2. Mylan |
  3. AllerGOS grant |
1000 Fördernummer
  1. -
  2. -
  3. -
1000 Förderprogramm
  1. -
  2. -
  3. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Novartis |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer Mylan |
    1000 Förderprogramm -
    1000 Fördernummer -
  3. 1000 joinedFunding-child
    1000 Förderer AllerGOS grant |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6427821.rdf
1000 Erstellt am 2021-06-01T09:15:37.021+0200
1000 Erstellt von 284
1000 beschreibt frl:6427821
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet Fri Oct 01 08:10:05 CEST 2021
1000 Objekt bearb. Fri Oct 01 08:09:52 CEST 2021
1000 Vgl. frl:6427821
1000 Oai Id
  1. oai:frl.publisso.de:frl:6427821 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source